Tumor Marker Diagnostic Technologies and Their Potential Market Applications

February 2012 | 110 pages | ID: T6F41C3BC63EN
Venture Planning Group

Abstracts

This 110-page report provides:

• Assessments and potential applications of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry and biosensors or tumor marker diagnostic testing.
• Review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy.

Contains 110 pages

Contents

CURRENT AND EMERGING TECHNOLOGIES

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
  a. Technological Principle
  b. Radioimmunoassay (RIA)
  c. Enzyme Immunoassays (EIA)
    Overview
    ELISA
    Immunofiltration
    Particle-Membrane Capture Immunoassay
    Enzyme Amplification
  d. Fluorescent Immunoassays
  e. Luminescence
    Chemiluminescence
    Bioluminescence
  f. Latex Agglutination
  g. Immunoprecipitation
  h. Affinity Chromatographu
  e. Liposome Flow-Injection Immunoassay
3. Molecular Diagnostics
  a. Technology Overview
  b. Amplification Methods
    PCR
    DAP-PCR
    Immuno-PCR
    QC-PCR
    CAR
    DNA
    HPA
    LCR
    NASBA
    QBR
    SDA
    3 SR, and others
4. Chromosome Analysis
  a. Chronic Myelogenous Leukemia (CML)
  b. Acute Myeloid Leukemia (AML)
  c. Acute Lymphoblastic Leukemia (ALL)
  d. Malignant Lymphomas Lymphoid Malignancies
  e. Chronic Lymphocytic Leukemia (CLL)
  f. Solid Cancers
  g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
  a. CT
  b. MRI
  c. NMR
  d. PET
  e. Photonics Spectroscopy